Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Product Name : BC LisPram
Product Type : Peptide
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide,Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.
Product Name : PramExe
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : Pramlintide,Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide,Insulin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XP-3924 resulted in 62% reduction of hyperglycemia after a glucose challenge. XP-3924 showed promising glucose control when compared to both Humulin R and co-administered injections of Humulin R & Symlin and it showed improved glucose control when compar...
Product Name : Xerisol
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 18, 2020
Lead Product(s) : Pramlintide,Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Juvenile Diabetes Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 17, 2015
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Juvenile Diabetes Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 26, 2013
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Juvenile Diabetes Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 16, 2012
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Juvenile Diabetes Research Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 07, 2010
Lead Product(s) : Pramlintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Amylin Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 20, 2010
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Amylin Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Amylin Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 04, 2010
Lead Product(s) : Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Amylin Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable